Phase II Study of nab-paclitaxel in Treated Patients with Advanced Non-Small Cell Lung Cancer
Not Applicable
- Conditions
- Treated patients with advanced non-small cell lung cancer
- Registration Number
- JPRN-UMIN000015841
- Lead Sponsor
- Tohoku Medical and Pharmaceutical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) Interstitial pneumonia/lung fibrosis on chest CT. 2) Previous drug allergy 3) History of poorly controlled pleural effusion, pericardial effusion and ascites. 4) Active infection. 5) Current Diarrhea. 6) Ileus or intestinal tract paralysis. 7) Symptomatic brain metastasis. 8) Active concomitant malignancy. 9) History of sever heart disease. 10) History of sever psychological disease. 11) Those judged to be not suitable by the attending physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method RR: response rate
- Secondary Outcome Measures
Name Time Method PFS: progression free survival OS: overall survival DCR: disease control rate Toxicity